Interesting Images18F-PSMA 1007 Uptake in Brain Metastases From Breast CancerMarafi, Fahad MD, KBNM*; Sasikumar, Arun MD†; Alfeeli, Mahmoud MD, KBNM*; Fathallah, Wael FRCR‡Author Information From the *Jaber Alahmad Centre for Molecular Imaging, Shuwaikh, Kuwait †St Gregorios International Cancer Care Centre, Parumala, Pathanmthitta, Kerala, India ‡Kuwait Cancer Control Centre, Shuwaikh, Kuwait. Received for publication May 2, 2019; revision accepted August 11, 2019. Conflicts of interest and sources of funding: none declared. Correspondence to: Arun Sasikumar, MD, Department of Nuclear Medicine, St Gregorios International Cancer Care Centre, Parumala, Pathanmthitta, Kerala, India. E-mail: email@example.com. Online date: October 31, 2019 Clinical Nuclear Medicine: February 2020 - Volume 45 - Issue 2 - p e77-e79 doi: 10.1097/RLU.0000000000002821 Buy Metrics Abstract A 64-year-old woman with metastatic breast cancer on follow-up had suspicious recurrent brain metastases. She underwent 18F-FDG PET/CT, 18F-PSMA 1007 brain PET/CT, and brain MRI. 18F-PSMA 1007 showed intense tracer localization in the suspected recurrent brain metastasis in right parietal lobe and also picked up 2 more metastatic brain lesions, which had concurrent findings of metastasis in subsequent MRI. Our case highlights the feasibility of 18F-PSMA 1007 PET/CT imaging of brain metastases from nonprostate cancers. It may be used as surrogate imaging tracer for potential theranostic application using alpha or beta emitters considering its similarity to PSMA-617. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.